First Clinical Trials Started in Israel

January 12, 2017

 

Alpha Tau Medical has initiated its first clinical trials with its Alpha DaRT (Diffusing Alpha–emitters Radiation Therapy) technology for the treatment of Squamous Cell Carcinoma (SCC) in Head, Neck and Skin at the Rabin Medical Center, Petah Tikva outside Tel Aviv.
The company is in the process of starting additional clinical trials in prostate cancer, breast cancer, colorectal cancer, gynecological cancer and pancreatic cancer.
The Alpha DaRT technology enables the possibility of providing brachytherapy treatment based on alpha emitters and has several advantages:
1.    Highly Potent and Ultra conformal
2.    Effective regardless of tumor oxygen level
3.    Short half-life – quick clinical results
4.    Negligible gamma radiation, no special shielding equipment is needed
5.    Disposable product – not capital equipment is needed
To keep up to date on our progress in the clinical trials, please follow us on LinkedIn, Twitter  or subscribe to our newsletter.

 

 

 

 

Share on Facebook
Share on Twitter
Please reload

Please reload

Featured Posts

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

1/5
Please reload

Archive
Please reload

Categories
Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

CONTACT US

Are you looking to participate in clinical trials?

Take our self-assessment test to find potentially suitable studies.

For other inquiries, please visit our contact page.